Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07687914 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma

Name: A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma — clinical trial record (NCT07687914)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Started2026-07-23

View on ClinicalTrials.gov ↗

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

10 trials monitored

See all monitored trials

Liver Cancer

1,505 trials monitored

See 60 trials at risk

This is a Phase 2, open-label, multicenter,study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and VEGF trap recombinant - Page 1 of 5 - protein) combine with IMM27M(Anti-CTLA-4 Humanized monoclonal antibody) in patients with advanced hepatocellular carcinoma who not have received the treatment for aHCC in past

Trial Details

NCT Number	NCT07687914
Lead Sponsor	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Conditions	HCC - Hepatocellular Carcinoma
Enrollment	50 participants
Start Date	2026-07-23
Primary Completion	2027-07-23 (estimated)
Study Completion	2028-07-23 (estimated)
Updated on ClinicalTrials.gov	2026-07-07